

Global Neuroendocrine Tumor Drug Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

<https://marketpublishers.com/r/GA223E86F855EN.html>

Date: July 2022

Pages: 118

Price: US\$ 3,480.00 (Single User License)

ID: GA223E86F855EN

Abstracts

The Neuroendocrine Tumor Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Neuroendocrine Tumor Drug market size is estimated to be worth US\$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Neuroendocrine Tumor Drug global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While mTOR Protein Inhibitors segment is altered to a % CAGR between 2022 and 2028.

Global key manufacturers of Neuroendocrine Tumor Drug include Eisai, Exelixis, Inc., Foresee Pharmaceuticals, LLC, Hutchison MediPharma Limited, and Intezyne, Inc, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Neuroendocrine Tumor Drug market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

mTOR Protein Inhibitors

Tyrosine Kinase 3 Inhibitors

Somatostatin Receptor Antagonists

Growth Hormone Releasing Factor Antagonists

Somatostatin Receptor Agonists

Others

Market segment by Application can be divided into

Hospital

Clinic

Others

The key market players for global Neuroendocrine Tumor Drug market are listed below:

Eisai

Exelixis, Inc.

Foresee Pharmaceuticals, LLC

Hutchison MediPharma Limited

Intezyne, Inc

INVENT Pharmaceuticals, Inc.

Ipsen S.A.

Jiangsu Hengrui Medicine Co., Ltd.

Karyopharm Therapeutics, Inc.

Lexicon Pharmaceuticals, Inc.

Midatech Pharma Plc .

Millennium Pharmaceuticals, Inc.

MolMed S.p.A.

Northwest Biotherapeutics, Inc.

Novartis AG

OctreoPharm Sciences GmbH

OXIGENE, Inc.

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Neuroendocrine Tumor Drug product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Neuroendocrine Tumor Drug, with price, sales, revenue and global market share of Neuroendocrine Tumor Drug from 2019 to 2022.

Chapter 3, the Neuroendocrine Tumor Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Neuroendocrine Tumor Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022. and Neuroendocrine Tumor Drug market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Neuroendocrine Tumor Drug.

Chapter 13, 14, and 15, to describe Neuroendocrine Tumor Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Contents

1 MARKET OVERVIEW

- 1.1 Neuroendocrine Tumor Drug Introduction
- 1.2 Market Analysis by Type
 - 1.2.1 Overview: Global Neuroendocrine Tumor Drug Revenue by Type: 2017 Versus 2021 Versus 2028
 - 1.2.2 mTOR Protein Inhibitors
 - 1.2.3 Tyrosine Kinase 3 Inhibitors
 - 1.2.4 Somatostatin Receptor Antagonists
 - 1.2.5 Growth Hormone Releasing Factor Antagonists
 - 1.2.6 Somatostatin Receptor Agonists
 - 1.2.7 Others
- 1.3 Market Analysis by Application
 - 1.3.1 Overview: Global Neuroendocrine Tumor Drug Revenue by Application: 2017 Versus 2021 Versus 2028
 - 1.3.2 Hospital
 - 1.3.3 Clinic
 - 1.3.4 Others
- 1.4 Global Neuroendocrine Tumor Drug Market Size & Forecast
 - 1.4.1 Global Neuroendocrine Tumor Drug Sales in Value (2017 & 2021 & 2028)
 - 1.4.2 Global Neuroendocrine Tumor Drug Sales in Volume (2017-2028)
 - 1.4.3 Global Neuroendocrine Tumor Drug Price (2017-2028)
- 1.5 Global Neuroendocrine Tumor Drug Production Capacity Analysis
 - 1.5.1 Global Neuroendocrine Tumor Drug Total Production Capacity (2017-2028)
 - 1.5.2 Global Neuroendocrine Tumor Drug Production Capacity by Geographic Region
- 1.6 Market Drivers, Restraints and Trends
 - 1.6.1 Neuroendocrine Tumor Drug Market Drivers
 - 1.6.2 Neuroendocrine Tumor Drug Market Restraints
 - 1.6.3 Neuroendocrine Tumor Drug Trends Analysis

2 MANUFACTURERS PROFILES

- 2.1 Eisai
 - 2.1.1 Eisai Details
 - 2.1.2 Eisai Major Business
 - 2.1.3 Eisai Neuroendocrine Tumor Drug Product and Services
 - 2.1.4 Eisai Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and

Market Share (2019, 2020, 2021, and 2022)

2.2 Exelixis, Inc.

2.2.1 Exelixis, Inc. Details

2.2.2 Exelixis, Inc. Major Business

2.2.3 Exelixis, Inc. Neuroendocrine Tumor Drug Product and Services

2.2.4 Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3 Foresee Pharmaceuticals, LLC

2.3.1 Foresee Pharmaceuticals, LLC Details

2.3.2 Foresee Pharmaceuticals, LLC Major Business

2.3.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product and Services

2.3.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4 Hutchison MediPharma Limited

2.4.1 Hutchison MediPharma Limited Details

2.4.2 Hutchison MediPharma Limited Major Business

2.4.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product and Services

2.4.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5 Intezyne, Inc

2.5.1 Intezyne, Inc Details

2.5.2 Intezyne, Inc Major Business

2.5.3 Intezyne, Inc Neuroendocrine Tumor Drug Product and Services

2.5.4 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6 INVENT Pharmaceuticals, Inc.

2.6.1 INVENT Pharmaceuticals, Inc. Details

2.6.2 INVENT Pharmaceuticals, Inc. Major Business

2.6.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product and Services

2.6.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7 Ipsen S.A.

2.7.1 Ipsen S.A. Details

2.7.2 Ipsen S.A. Major Business

2.7.3 Ipsen S.A. Neuroendocrine Tumor Drug Product and Services

2.7.4 Ipsen S.A. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin

and Market Share (2019, 2020, 2021, and 2022)

2.8 Jiangsu Hengrui Medicine Co., Ltd.

2.8.1 Jiangsu Hengrui Medicine Co., Ltd. Details

2.8.2 Jiangsu Hengrui Medicine Co., Ltd. Major Business

2.8.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product and Services

2.8.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9 Karyopharm Therapeutics, Inc.

2.9.1 Karyopharm Therapeutics, Inc. Details

2.9.2 Karyopharm Therapeutics, Inc. Major Business

2.9.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product and Services

2.9.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10 Lexicon Pharmaceuticals, Inc.

2.10.1 Lexicon Pharmaceuticals, Inc. Details

2.10.2 Lexicon Pharmaceuticals, Inc. Major Business

2.10.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product and Services

2.10.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11 Midatech Pharma Plc .

2.11.1 Midatech Pharma Plc . Details

2.11.2 Midatech Pharma Plc . Major Business

2.11.3 Midatech Pharma Plc . Neuroendocrine Tumor Drug Product and Services

2.11.4 Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12 Millennium Pharmaceuticals, Inc.

2.12.1 Millennium Pharmaceuticals, Inc. Details

2.12.2 Millennium Pharmaceuticals, Inc. Major Business

2.12.3 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product and Services

2.12.4 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13 MolMed S.p.A.

2.13.1 MolMed S.p.A. Details

2.13.2 MolMed S.p.A. Major Business

2.13.3 MolMed S.p.A. Neuroendocrine Tumor Drug Product and Services

2.13.4 MolMed S.p.A. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14 Northwest Biotherapeutics, Inc.

2.14.1 Northwest Biotherapeutics, Inc. Details

2.14.2 Northwest Biotherapeutics, Inc. Major Business

2.14.3 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product and Services

2.14.4 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.15 Novartis AG

2.15.1 Novartis AG Details

2.15.2 Novartis AG Major Business

2.15.3 Novartis AG Neuroendocrine Tumor Drug Product and Services

2.15.4 Novartis AG Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.16 OctreoPharm Sciences GmbH

2.16.1 OctreoPharm Sciences GmbH Details

2.16.2 OctreoPharm Sciences GmbH Major Business

2.16.3 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product and Services

2.16.4 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.17 OXiGENE, Inc.

2.17.1 OXiGENE, Inc. Details

2.17.2 OXiGENE, Inc. Major Business

2.17.3 OXiGENE, Inc. Neuroendocrine Tumor Drug Product and Services

2.17.4 OXiGENE, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

3 NEUROENDOCRINE TUMOR DRUG BREAKDOWN DATA BY MANUFACTURER

3.1 Global Neuroendocrine Tumor Drug Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)

3.2 Global Neuroendocrine Tumor Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022)

3.3 Key Manufacturer Market Position in Neuroendocrine Tumor Drug

3.4 Market Concentration Rate

3.4.1 Top 3 Neuroendocrine Tumor Drug Manufacturer Market Share in 2021

3.4.2 Top 6 Neuroendocrine Tumor Drug Manufacturer Market Share in 2021

3.5 Global Neuroendocrine Tumor Drug Production Capacity by Company: 2021 VS 2022

3.6 Manufacturer by Geography: Head Office and Neuroendocrine Tumor Drug Production Site

3.7 New Entrant and Capacity Expansion Plans

3.8 Mergers & Acquisitions

4 MARKET ANALYSIS BY REGION

4.1 Global Neuroendocrine Tumor Drug Market Size by Region

4.1.1 Global Neuroendocrine Tumor Drug Sales in Volume by Region (2017-2028)

4.1.2 Global Neuroendocrine Tumor Drug Revenue by Region (2017-2028)

4.2 North America Neuroendocrine Tumor Drug Revenue (2017-2028)

4.3 Europe Neuroendocrine Tumor Drug Revenue (2017-2028)

4.4 Asia-Pacific Neuroendocrine Tumor Drug Revenue (2017-2028)

4.5 South America Neuroendocrine Tumor Drug Revenue (2017-2028)

4.6 Middle East and Africa Neuroendocrine Tumor Drug Revenue (2017-2028)

5 MARKET SEGMENT BY TYPE

5.1 Global Neuroendocrine Tumor Drug Sales in Volume by Type (2017-2028)

5.2 Global Neuroendocrine Tumor Drug Revenue by Type (2017-2028)

5.3 Global Neuroendocrine Tumor Drug Price by Type (2017-2028)

6 MARKET SEGMENT BY APPLICATION

6.1 Global Neuroendocrine Tumor Drug Sales in Volume by Application (2017-2028)

6.2 Global Neuroendocrine Tumor Drug Revenue by Application (2017-2028)

6.3 Global Neuroendocrine Tumor Drug Price by Application (2017-2028)

7 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION

7.1 North America Neuroendocrine Tumor Drug Sales by Type (2017-2028)

7.2 North America Neuroendocrine Tumor Drug Sales by Application (2017-2028)

7.3 North America Neuroendocrine Tumor Drug Market Size by Country

7.3.1 North America Neuroendocrine Tumor Drug Sales in Volume by Country (2017-2028)

7.3.2 North America Neuroendocrine Tumor Drug Revenue by Country (2017-2028)

7.3.3 United States Market Size and Forecast (2017-2028)

7.3.4 Canada Market Size and Forecast (2017-2028)

7.3.5 Mexico Market Size and Forecast (2017-2028)

8 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION

8.1 Europe Neuroendocrine Tumor Drug Sales by Type (2017-2028)

8.2 Europe Neuroendocrine Tumor Drug Sales by Application (2017-2028)

8.3 Europe Neuroendocrine Tumor Drug Market Size by Country

8.3.1 Europe Neuroendocrine Tumor Drug Sales in Volume by Country (2017-2028)

8.3.2 Europe Neuroendocrine Tumor Drug Revenue by Country (2017-2028)

8.3.3 Germany Market Size and Forecast (2017-2028)

8.3.4 France Market Size and Forecast (2017-2028)

8.3.5 United Kingdom Market Size and Forecast (2017-2028)

8.3.6 Russia Market Size and Forecast (2017-2028)

8.3.7 Italy Market Size and Forecast (2017-2028)

9 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION

9.1 Asia-Pacific Neuroendocrine Tumor Drug Sales by Type (2017-2028)

9.2 Asia-Pacific Neuroendocrine Tumor Drug Sales by Application (2017-2028)

9.3 Asia-Pacific Neuroendocrine Tumor Drug Market Size by Region

9.3.1 Asia-Pacific Neuroendocrine Tumor Drug Sales in Volume by Region (2017-2028)

9.3.2 Asia-Pacific Neuroendocrine Tumor Drug Revenue by Region (2017-2028)

9.3.3 China Market Size and Forecast (2017-2028)

9.3.4 Japan Market Size and Forecast (2017-2028)

9.3.5 Korea Market Size and Forecast (2017-2028)

9.3.6 India Market Size and Forecast (2017-2028)

9.3.7 Southeast Asia Market Size and Forecast (2017-2028)

9.3.8 Australia Market Size and Forecast (2017-2028)

10 SOUTH AMERICA BY REGION, BY TYPE, AND BY APPLICATION

10.1 South America Neuroendocrine Tumor Drug Sales by Type (2017-2028)

10.2 South America Neuroendocrine Tumor Drug Sales by Application (2017-2028)

10.3 South America Neuroendocrine Tumor Drug Market Size by Country

10.3.1 South America Neuroendocrine Tumor Drug Sales in Volume by Country (2017-2028)

10.3.2 South America Neuroendocrine Tumor Drug Revenue by Country (2017-2028)

10.3.3 Brazil Market Size and Forecast (2017-2028)

10.3.4 Argentina Market Size and Forecast (2017-2028)

11 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION

11.1 Middle East & Africa Neuroendocrine Tumor Drug Sales by Type (2017-2028)

11.2 Middle East & Africa Neuroendocrine Tumor Drug Sales by Application
(2017-2028)

11.3 Middle East & Africa Neuroendocrine Tumor Drug Market Size by Country

11.3.1 Middle East & Africa Neuroendocrine Tumor Drug Sales in Volume by Country
(2017-2028)

11.3.2 Middle East & Africa Neuroendocrine Tumor Drug Revenue by Country
(2017-2028)

11.3.3 Turkey Market Size and Forecast (2017-2028)

11.3.4 Egypt Market Size and Forecast (2017-2028)

11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)

11.3.6 South Africa Market Size and Forecast (2017-2028)

12 RAW MATERIAL AND INDUSTRY CHAIN

12.1 Raw Material of Neuroendocrine Tumor Drug and Key Manufacturers

12.2 Manufacturing Costs Percentage of Neuroendocrine Tumor Drug

12.3 Neuroendocrine Tumor Drug Production Process

12.4 Neuroendocrine Tumor Drug Industrial Chain

13 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.2 Neuroendocrine Tumor Drug Typical Distributors

13.3 Neuroendocrine Tumor Drug Typical Customers

14 RESEARCH FINDINGS AND CONCLUSION

15 APPENDIX

15.1 Methodology

15.2 Research Process and Data Source

15.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. Global Neuroendocrine Tumor Drug Revenue by Type, (USD Million), 2017 & 2021 & 2028
- Table 2. Global Neuroendocrine Tumor Drug Revenue by Application, (USD Million), 2017 & 2021 & 2028
- Table 3. Eisai Basic Information, Manufacturing Base and Competitors
- Table 4. Eisai Major Business
- Table 5. Eisai Neuroendocrine Tumor Drug Product and Services
- Table 6. Eisai Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
- Table 7. Exelixis, Inc. Basic Information, Manufacturing Base and Competitors
- Table 8. Exelixis, Inc. Major Business
- Table 9. Exelixis, Inc. Neuroendocrine Tumor Drug Product and Services
- Table 10. Exelixis, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
- Table 11. Foresee Pharmaceuticals, LLC Basic Information, Manufacturing Base and Competitors
- Table 12. Foresee Pharmaceuticals, LLC Major Business
- Table 13. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product and Services
- Table 14. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
- Table 15. Hutchison MediPharma Limited Basic Information, Manufacturing Base and Competitors
- Table 16. Hutchison MediPharma Limited Major Business
- Table 17. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product and Services
- Table 18. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
- Table 19. Intezyne, Inc Basic Information, Manufacturing Base and Competitors
- Table 20. Intezyne, Inc Major Business
- Table 21. Intezyne, Inc Neuroendocrine Tumor Drug Product and Services
- Table 22. Intezyne, Inc Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 23. INVENT Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors

Table 24. INVENT Pharmaceuticals, Inc. Major Business

Table 25. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product and Services

Table 26. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 27. Ipsen S.A. Basic Information, Manufacturing Base and Competitors

Table 28. Ipsen S.A. Major Business

Table 29. Ipsen S.A. Neuroendocrine Tumor Drug Product and Services

Table 30. Ipsen S.A. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 31. Jiangsu Hengrui Medicine Co., Ltd. Basic Information, Manufacturing Base and Competitors

Table 32. Jiangsu Hengrui Medicine Co., Ltd. Major Business

Table 33. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product and Services

Table 34. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 35. Karyopharm Therapeutics, Inc. Basic Information, Manufacturing Base and Competitors

Table 36. Karyopharm Therapeutics, Inc. Major Business

Table 37. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product and Services

Table 38. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 39. Lexicon Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors

Table 40. Lexicon Pharmaceuticals, Inc. Major Business

Table 41. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product and Services

Table 42. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 43. Midatech Pharma Plc . Basic Information, Manufacturing Base and Competitors

Table 44. Midatech Pharma Plc . Major Business

Table 45. Midatech Pharma Plc . Neuroendocrine Tumor Drug Product and Services

Table 46. Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 47. Millennium Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors

Table 48. Millennium Pharmaceuticals, Inc. Major Business

Table 49. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product and Services

Table 50. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 51. MolMed S.p.A. Basic Information, Manufacturing Base and Competitors

Table 52. MolMed S.p.A. Major Business

Table 53. MolMed S.p.A. Neuroendocrine Tumor Drug Product and Services

Table 54. MolMed S.p.A. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 55. Northwest Biotherapeutics, Inc. Basic Information, Manufacturing Base and Competitors

Table 56. Northwest Biotherapeutics, Inc. Major Business

Table 57. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product and Services

Table 58. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 59. Novartis AG Basic Information, Manufacturing Base and Competitors

Table 60. Novartis AG Major Business

Table 61. Novartis AG Neuroendocrine Tumor Drug Product and Services

Table 62. Novartis AG Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 63. OctreoPharm Sciences GmbH Basic Information, Manufacturing Base and Competitors

Table 64. OctreoPharm Sciences GmbH Major Business

Table 65. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product and Services

Table 66. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

- Table 67. OXiGENE, Inc. Basic Information, Manufacturing Base and Competitors
- Table 68. OXiGENE, Inc. Major Business
- Table 69. OXiGENE, Inc. Neuroendocrine Tumor Drug Product and Services
- Table 70. OXiGENE, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
- Table 71. Global Neuroendocrine Tumor Drug Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Pcs)
- Table 72. Global Neuroendocrine Tumor Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
- Table 73. Market Position of Manufacturers in Neuroendocrine Tumor Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
- Table 74. Global Neuroendocrine Tumor Drug Production Capacity by Company, (K Pcs): 2020 VS 2021
- Table 75. Head Office and Neuroendocrine Tumor Drug Production Site of Key Manufacturer
- Table 76. Neuroendocrine Tumor Drug New Entrant and Capacity Expansion Plans
- Table 77. Neuroendocrine Tumor Drug Mergers & Acquisitions in the Past Five Years
- Table 78. Global Neuroendocrine Tumor Drug Sales by Region (2017-2022) & (K Pcs)
- Table 79. Global Neuroendocrine Tumor Drug Sales by Region (2023-2028) & (K Pcs)
- Table 80. Global Neuroendocrine Tumor Drug Revenue by Region (2017-2022) & (USD Million)
- Table 81. Global Neuroendocrine Tumor Drug Revenue by Region (2023-2028) & (USD Million)
- Table 82. Global Neuroendocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
- Table 83. Global Neuroendocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
- Table 84. Global Neuroendocrine Tumor Drug Revenue by Type (2017-2022) & (USD Million)
- Table 85. Global Neuroendocrine Tumor Drug Revenue by Type (2023-2028) & (USD Million)
- Table 86. Global Neuroendocrine Tumor Drug Price by Type (2017-2022) & (USD/Pcs)
- Table 87. Global Neuroendocrine Tumor Drug Price by Type (2023-2028) & (USD/Pcs)
- Table 88. Global Neuroendocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
- Table 89. Global Neuroendocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
- Table 90. Global Neuroendocrine Tumor Drug Revenue by Application (2017-2022) & (USD Million)
- Table 91. Global Neuroendocrine Tumor Drug Revenue by Application (2023-2028) & (USD Million)

Table 92. Global Neuroendocrine Tumor Drug Price by Application (2017-2022) & (USD/Pcs)

Table 93. Global Neuroendocrine Tumor Drug Price by Application (2023-2028) & (USD/Pcs)

Table 94. North America Neuroendocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)

Table 95. North America Neuroendocrine Tumor Drug Sales by Country (2023-2028) & (K Pcs)

Table 96. North America Neuroendocrine Tumor Drug Revenue by Country (2017-2022) & (USD Million)

Table 97. North America Neuroendocrine Tumor Drug Revenue by Country (2023-2028) & (USD Million)

Table 98. North America Neuroendocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)

Table 99. North America Neuroendocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)

Table 100. North America Neuroendocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)

Table 101. North America Neuroendocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)

Table 102. Europe Neuroendocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)

Table 103. Europe Neuroendocrine Tumor Drug Sales by Country (2023-2028) & (K Pcs)

Table 104. Europe Neuroendocrine Tumor Drug Revenue by Country (2017-2022) & (USD Million)

Table 105. Europe Neuroendocrine Tumor Drug Revenue by Country (2023-2028) & (USD Million)

Table 106. Europe Neuroendocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)

Table 107. Europe Neuroendocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)

Table 108. Europe Neuroendocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)

Table 109. Europe Neuroendocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)

Table 110. Asia-Pacific Neuroendocrine Tumor Drug Sales by Region (2017-2022) & (K Pcs)

Table 111. Asia-Pacific Neuroendocrine Tumor Drug Sales by Region (2023-2028) & (K Pcs)

Table 112. Asia-Pacific Neuroendocrine Tumor Drug Revenue by Region (2017-2022) &

(USD Million)

Table 113. Asia-Pacific Neuroendocrine Tumor Drug Revenue by Region (2023-2028) & (USD Million)

Table 114. Asia-Pacific Neuroendocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)

Table 115. Asia-Pacific Neuroendocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)

Table 116. Asia-Pacific Neuroendocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)

Table 117. Asia-Pacific Neuroendocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)

Table 118. South America Neuroendocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)

Table 119. South America Neuroendocrine Tumor Drug Sales by Country (2023-2028) & (K Pcs)

Table 120. South America Neuroendocrine Tumor Drug Revenue by Country (2017-2022) & (USD Million)

Table 121. South America Neuroendocrine Tumor Drug Revenue by Country (2023-2028) & (USD Million)

Table 122. South America Neuroendocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)

Table 123. South America Neuroendocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)

Table 124. South America Neuroendocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)

Table 125. South America Neuroendocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)

Table 126. Middle East & Africa Neuroendocrine Tumor Drug Sales by Region (2017-2022) & (K Pcs)

Table 127. Middle East & Africa Neuroendocrine Tumor Drug Sales by Region (2023-2028) & (K Pcs)

Table 128. Middle East & Africa Neuroendocrine Tumor Drug Revenue by Region (2017-2022) & (USD Million)

Table 129. Middle East & Africa Neuroendocrine Tumor Drug Revenue by Region (2023-2028) & (USD Million)

Table 130. Middle East & Africa Neuroendocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)

Table 131. Middle East & Africa Neuroendocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)

Table 132. Middle East & Africa Neuroendocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)

Table 133. Middle East & Africa Neuroendocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)

Table 134. Neuroendocrine Tumor Drug Raw Material

Table 135. Key Manufacturers of Neuroendocrine Tumor Drug Raw Materials

Table 136. Direct Channel Pros & Cons

Table 137. Indirect Channel Pros & Cons

Table 138. Neuroendocrine Tumor Drug Typical Distributors

Table 139. Neuroendocrine Tumor Drug Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Neuroendocrine Tumor Drug Picture

Figure 2. Global Neuroendocrine Tumor Drug Revenue Market Share by Type in 2021

Figure 3. mTOR Protein Inhibitors

Figure 4. Tyrosine Kinase 3 Inhibitors

Figure 5. Somatostatin Receptor Antagonists

Figure 6. Growth Hormone Releasing Factor Antagonists

Figure 7. Somatostatin Receptor Agonists

Figure 8. Others

Figure 9. Global Neuroendocrine Tumor Drug Revenue Market Share by Application in 2021

Figure 10. Hospital

Figure 11. Clinic

Figure 12. Others

Figure 13. Global Neuroendocrine Tumor Drug Revenue, (USD Million) & (K Pcs): 2017 & 2021 & 2028

Figure 14. Global Neuroendocrine Tumor Drug Revenue and Forecast (2017-2028) & (USD Million)

Figure 15. Global Neuroendocrine Tumor Drug Sales (2017-2028) & (K Pcs)

Figure 16. Global Neuroendocrine Tumor Drug Price (2017-2028) & (USD/Pcs)

Figure 17. Global Neuroendocrine Tumor Drug Production Capacity (2017-2028) & (K Pcs)

Figure 18. Global Neuroendocrine Tumor Drug Production Capacity by Geographic Region: 2022 VS 2028

Figure 19. Neuroendocrine Tumor Drug Market Drivers

Figure 20. Neuroendocrine Tumor Drug Market Restraints

Figure 21. Neuroendocrine Tumor Drug Market Trends

Figure 22. Global Neuroendocrine Tumor Drug Sales Market Share by Manufacturer in 2021

Figure 23. Global Neuroendocrine Tumor Drug Revenue Market Share by Manufacturer in 2021

Figure 24. Neuroendocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021

Figure 25. Top 3 Neuroendocrine Tumor Drug Manufacturer (Revenue) Market Share in 2021

Figure 26. Top 6 Neuroendocrine Tumor Drug Manufacturer (Revenue) Market Share in

2021

Figure 27. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2017-2028)

Figure 28. Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2017-2028)

Figure 29. North America Neuroendocrine Tumor Drug Revenue (2017-2028) & (USD Million)

Figure 30. Europe Neuroendocrine Tumor Drug Revenue (2017-2028) & (USD Million)

Figure 31. Asia-Pacific Neuroendocrine Tumor Drug Revenue (2017-2028) & (USD Million)

Figure 32. South America Neuroendocrine Tumor Drug Revenue (2017-2028) & (USD Million)

Figure 33. Middle East & Africa Neuroendocrine Tumor Drug Revenue (2017-2028) & (USD Million)

Figure 34. Global Neuroendocrine Tumor Drug Sales Market Share by Type (2017-2028)

Figure 35. Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2017-2028)

Figure 36. Global Neuroendocrine Tumor Drug Price by Type (2017-2028) & (USD/Pcs)

Figure 37. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2017-2028)

Figure 38. Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2017-2028)

Figure 39. Global Neuroendocrine Tumor Drug Price by Application (2017-2028) & (USD/Pcs)

Figure 40. North America Neuroendocrine Tumor Drug Sales Market Share by Type (2017-2028)

Figure 41. North America Neuroendocrine Tumor Drug Sales Market Share by Application (2017-2028)

Figure 42. North America Neuroendocrine Tumor Drug Sales Market Share by Country (2017-2028)

Figure 43. North America Neuroendocrine Tumor Drug Revenue Market Share by Country (2017-2028)

Figure 44. United States Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 45. Canada Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 46. Mexico Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

- Figure 47. Europe Neuroendocrine Tumor Drug Sales Market Share by Type (2017-2028)
- Figure 48. Europe Neuroendocrine Tumor Drug Sales Market Share by Application (2017-2028)
- Figure 49. Europe Neuroendocrine Tumor Drug Sales Market Share by Country (2017-2028)
- Figure 50. Europe Neuroendocrine Tumor Drug Revenue Market Share by Country (2017-2028)
- Figure 51. Germany Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
- Figure 52. France Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
- Figure 53. United Kingdom Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
- Figure 54. Russia Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
- Figure 55. Italy Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
- Figure 56. Asia-Pacific Neuroendocrine Tumor Drug Sales Market Share by Region (2017-2028)
- Figure 57. Asia-Pacific Neuroendocrine Tumor Drug Sales Market Share by Application (2017-2028)
- Figure 58. Asia-Pacific Neuroendocrine Tumor Drug Sales Market Share by Region (2017-2028)
- Figure 59. Asia-Pacific Neuroendocrine Tumor Drug Revenue Market Share by Region (2017-2028)
- Figure 60. China Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
- Figure 61. Japan Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
- Figure 62. Korea Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
- Figure 63. India Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
- Figure 64. Southeast Asia Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
- Figure 65. Australia Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
- Figure 66. South America Neuroendocrine Tumor Drug Sales Market Share by Type

(2017-2028)

Figure 67. South America Neuroendocrine Tumor Drug Sales Market Share by Application (2017-2028)

Figure 68. South America Neuroendocrine Tumor Drug Sales Market Share by Country (2017-2028)

Figure 69. South America Neuroendocrine Tumor Drug Revenue Market Share by Country (2017-2028)

Figure 70. Brazil Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. Argentina Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 72. Middle East & Africa Neuroendocrine Tumor Drug Sales Market Share by Type (2017-2028)

Figure 73. Middle East & Africa Neuroendocrine Tumor Drug Sales Market Share by Application (2017-2028)

Figure 74. Middle East & Africa Neuroendocrine Tumor Drug Sales Market Share by Region (2017-2028)

Figure 75. Middle East & Africa Neuroendocrine Tumor Drug Revenue Market Share by Region (2017-2028)

Figure 76. Turkey Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 77. Egypt Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 78. Saudi Arabia Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 79. South Africa Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. Manufacturing Cost Structure Analysis of Neuroendocrine Tumor Drug in 2021

Figure 81. Manufacturing Process Analysis of Neuroendocrine Tumor Drug

Figure 82. Neuroendocrine Tumor Drug Industrial Chain

Figure 83. Sales Channel: Direct Channel vs Indirect Channel

Figure 84. Methodology

Figure 85. Research Process and Data Source

I would like to order

Product name: Global Neuroendocrine Tumor Drug Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

Product link: <https://marketpublishers.com/r/GA223E86F855EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA223E86F855EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

